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Abstract 
Observational epidemiological studies have found an association between schizophrenia 
and breast cancer, but it is not known if the relationship is a causal one. We used summary 
statistics from very large genome-wide association studies of schizophrenia (n = 40,675 
cases and 64,643 controls) and breast cancer (n = 122,977 cases and 105,974 controls) to 
investigate whether there is evidence that the association is partly due to shared genetic 
risk factors and whether there is evidence of a causal relationship.  
Using LD-score regression, we found that there is a small but significant genetic 
correlation between the two disorders (rG = 0.14, S.E = 0.03, p = 4.75 x 10-8), indicating 
shared genetic risk factors. Using 142 genetic variants associated with schizophrenia as 
instrumental variables that are a proxy for having schizophrenia, we estimated a causal 
effect of schizophrenia on breast cancer on the observed scale as bxy = 0.032 (S.E. = 0.009, p 
= 2.3 x 10-4). A one standard deviation increase in liability to schizophrenia increases risk of 
breast cancer 1.09-fold. In contrast, the estimated causal effect of breast cancer on 
schizophrenia from 191 instruments was not significantly different from zero (bxy = -0.005, 
S.E. = 0.012, p =0.67). No evidence for pleiotropy was found and adjusting for the effects of 
smoking or parity did not alter the results.  
These results provide evidence that the previously observed association is due to 
schizophrenia causally increasing risk for breast cancer. Genetic variants may provide an 
avenue to elucidating the mechanism underpinning this relationship. 
 
Keywords: Mendelian Randomisation; causality; epidemiology; genetic correlation; 
pleiotropy 
 
Introduction 
Individuals diagnosed with schizophrenia have increased mortality compared to the general 
population with a life expectancy of 10-15 years less than those without the disorder(1). 
Despite having increased levels of risk factors for cancer such as smoking and physical 
inactivity, epidemiological studies have found evidence that the age-specific incidence rates 
of most cancers are lower in patients with schizophrenia compared to the general 
population (2). Breast cancer is an exception to this trend, with several studies showing 
increased risk in women with schizophrenia. A systematic review of 13 studies found that six 
studies observed an increased risk in schizophrenia patients (3), and the three largest 
studies estimated standardized incidence ratios (SIR) of 1.11 (1.00–1.22)(4), 1.20 (1.05–
1.38)(5) and 1.15 (0.98–1.34)(6). More recently, a study of insurance claims data in Taiwan 
found that the risk of breast cancer in female schizophrenia patients after adjustment for 
confounders was 1.94 (95% CI: 1.43-2.63)(7). Another meta-analysis including data from 
125,760 women estimated an SIR of 1.31 (95%CI: 1.14-1.50)(8). 
 The mechanism behind the increased rate of breast cancer among schizophrenia 
patients is unknown. A key question of interest is if the relationship is due to shared genetic 
and/or lifestyle risk factors or a consequence of the disease itself (e.g., related to the 
disease process or treatment). Here, we use genome-wide association study (GWAS) 
summary statistics results to investigate the genetic relationship between schizophrenia and 
breast cancer. First, we investigate if there is a genetic correlation between the two 
disorders using Single Nucleotide Polymorphisms (SNPs) throughout the genome. Second, 
we investigate if there is evidence of a causal relationship between the two disorders using 
Mendelian Randomisation (9).  
 
 Methods 
Analyses used summary statistics from the Breast Cancer Consortium (BCAC) GWAS (10) of 
122,977 cases and 105,974 controls for 11,792,543 SNPs and from the schizophrenia 
working group of the Psychiatric Genomics Consortium (11) of 40,675 cases and 64,643 
controls for 5,471,613 SNPs. Merging the two data sets, retaining only HapMap 3 SNPs that 
were genotyped or well imputed in both, gave 937,918 SNPs for use in LD-score regression 
(LDSR) (12, 13) analyses. LDSR was used to estimate both the heritability attributable to 
common SNPs for both schizophrenia and breast cancer, as well as the genetic correlation 
between the two disorders.  
Generalised Summary-based Mendelian Randomisation (GSMR) (14) was used to 
evaluate the hypothesis that having schizophrenia (or the disease process leading to its 
development) is causally related to breast cancer risk, rather than the relationship being 
due to pleiotropy (the same genes having independent effects on both disorders) or to 
shared lifestyle factors. Mendelian Randomisation (MR) is a form of instrumental variable 
analysis that uses genetic variants associated with the exposure of interest as instrument-
based predictors of the exposure which are a proxy of the exposure, to estimate the causal 
effect (bxy) of the exposure (x) on the outcome (y). In this study, we used genetic variants 
significantly associated with schizophrenia as instrument-based predictors of schizophrenia.  
We tested whether these instruments were associated with breast cancer, and conversely 
whether genetic variants associated with breast cancer risks were associated with 
schizophrenia. Under a model of causality where schizophrenia causally increases risk of 
breast cancer, we expect bxy for schizophrenia as exposure, but not bxy for breast cancer as 
exposure, to be significantly greater than zero. GSMR uses generalised least squares to 
estimate bxy and is more powerful than other commonly used MR methods because it 
appropriately accounts for the errors in the effect size estimates of the SNP instruments. 
Results from other MR methods are shown for comparison (Supplementary Table 1). 
 To derive sets of independent SNPs to use as instruments for schizophrenia and 
breast cancer respectively, we conducted LD-clumping using PLINK retaining SNPs with LD r2 
< 0.005 and at least 5MB apart were included. This generated a list of essentially 
independent genome-wide significant SNPs for schizophrenia, and also for breast cancer. 
The GSMR analysis model fits a correlation matrix which accounts for any residual 
correlation between instruments.  
A key assumption underlying inference of causality from MR analysis is that there is 
no pleiotropy –  for example, in the case of breast cancer as the outcome trait and 
schizophrenia as the exposure, the key assumption is that SNPs do not influence breast 
cancer other than through the pathway that influences schizophrenia risk. To improve 
robustness of MR estimates, GSMR uses a heterogeneity test (called HEIDI-outlier) to assess 
the estimate of bxy at each of the instrument SNPs. SNPs that are extreme outliers in bxy 
estimate may indicate locus-specific pleiotropy and we therefore excluded such SNPs from 
the analysis. 
 
Sensitivity analyses – adjusting for smoking 
One potential mechanism for increased risk of breast cancer in schizophrenia patients is 
smoking. Schizophrenia patients smoke at higher rate than the general population (15) and 
smoking is a modest risk factor for breast cancer (16). Moreover, one of the genome-wide 
significant SNPs for schizophrenia (rs3743078-C, bscz = -0.07, S.E. = 0.01, p = 3.11 x 10
-12) is 
located in a subunit of the nicotinic receptor (CHRNA3), a gene known to be associated with 
smoking and increased risk for lung cancer (17).  
We investigated in two ways whether there was any evidence that the potential 
causal association between schizophrenia and breast cancer was driven by smoking. First, 
we removed SNP rs3743078 as an instrument and conducted the GSMR analysis again. 
Secondly, we conducted a multi-trait conditional analysis (mtCOJO) to adjust the 
schizophrenia summary statistics for the effect of heaviness of smoking. To achieve this, a 
GWAS of self-reported number of cigarettes smoked per day (CPD) was collected from 
32,510 people within the UK Biobank (18). We adjusted the phenotype by sex and age, and 
then performed BOLT-LMM (19) with the first 10 principal components fitted as covariates. 
Three independent genome-wide significant SNPs that did not show evidence of pleiotropy 
were then used to conduct a GSMR analysis to estimate the causal effect of smoking 
heaviness on schizophrenia. The schizophrenia summary statistics were then adjusted for 
the estimated causal effect of CPD according to the method described in Zhu et al(14). The 
adjusted trait - denoted schizophrenia adjusted for cigarettes per day (SCZ_adj_CPD) - was 
tested for causal association with breast cancer. 
 
Adjusting for parity 
Another factor that might underlie any association between schizophrenia and breast 
cancer is parity. Increased parity is protective for breast cancer (20) and patients with 
schizophrenia have fewer children compared to the general population (21). To investigate 
this, we conducted an mtCOJO analysis to adjust for the causal effect of parity on breast 
cancer using results from a GWAS analysis of number of children ever born in women from 
the UK Biobank. Results were downloaded from                                                 
http://www.nealelab.is/uk-biobank/. A description of the QC steps and analysis are given at 
http://www.nealelab.is/blog/2017/9/11/details-and-considerations-of-the-uk-biobank-
gwas. A GWAS of number of live births was conducted in 193,953 unrelated women of 
white British descent. The phenotype was coded into three categories: less than 2 children, 
2 children and more than 2 children and analysis conducted with 10 principal components 
as covariates. The GWAS effect size estimates were recoded so that they corresponded to 
the effect on having fewer children. Using the genome-wide significant SNPs that passed the 
HEIDI test, we estimated the causal effect of reduced parity on breast cancer. There were 
not enough SNPs that were genome-wide significant and passed the HEIDI outlier test, so 
we included SNPs with a p-value for association with parity less than 1 x 10-7. We then 
conducted an mtCOJO analysis to adjust the breast cancer summary statistics for the causal 
effect of reduced parity (bc_adj_parity) and then tested for a causal effect of schizophrenia 
on the adjusted trait. 
 
Results 
LD-score Regression 
The estimated heritability on the liability scale explained by common SNPs was 0.15 
(Standard Error (S.E.) = 0.01) for breast cancer (assuming a population lifetime risk of 0.12 
and sample prevalence of 0.54) and 0.23 (S.E. = 0.008) for schizophrenia (assuming a 
population lifetime risk of 0.01 and sample prevalence of 0.42). The genetic correlation (rG) 
between schizophrenia and breast cancer was 0.14 (S.E = 0.03, p = 4.75 x 10-8), identical to 
that found in previous analyses using summary statistics from smaller studies of 
schizophrenia and breast cancer (22), indicating there are shared genetic risk factors 
between the two disorders.  
  MR analysis 
 
We used GSMR to investigate if the significant genetic correlation was due to a 
causal relationship between schizophrenia and breast cancer. Results are presented in Table 
1.  
 
 
Table 1. Results from Mendelian Randomisation analysis  
 
Exposure Exposure 
Sample 
Size 
Outcome Number of 
independent 
instruments 
Instrum
ents 
remove
d by 
HEIDI 
test 
Number of 
instruments 
used in GSMR 
bxy S.E. pvalue 
Schizophrenia 105,318 
 
Breast Cancer 150 8 142 0.032 0.008 2.19E-04 
Breast Cancer 228,951 Schizophrenia 204 13 191 -0.005 0.012 0.67 
 
A total of 150 independent SNPs that were associated with schizophrenia at p<5x10-8 were 
used, of which eight were filtered by the HEIDI outlier test, leaving 142 SNPs for analysis. 
The GSMR estimate of schizophrenia on breast cancer (bxy) was estimated as 0.032 (S.E. = 
0.008, p = 2.2 x 10-4) (Figure 1a), indicating evidence for a causal effect. Transforming the 
estimate to the more interpretable scale (i.e. fold increase in risk per 1 standard deviation 
(SD) increase in liability to schizophrenia) gives an odds ratio (OR) of 1.09 (S.E. = 0.008). 
By contrast, there was no evidence of a causal effect of breast cancer on 
schizophrenia, using 191 SNPs as instruments after HEIDI-outlier filtering removed 13 SNPs 
(bxy = -0.005, S.E. = 0.012, p = 0.67) (Figure 1b). Other commonly used MR methods such as 
MR-Egger (23) and inverse-variance weighted MR (aka MR-IVW) were consistent with those 
found using GSMR (Supplementary Table 1). The intercept from MR-Egger regression, a 
measure of pleiotropy, was not significantly different from 0 (p = 0.95) when including all 
SNPs. 
 
Schizophrenia, smoking and breast cancer 
Removing the SNP in CHRNA3 that is associated with smoking and schizophrenia 
(rs3743078) did not affect the results (bxy = 0.032, S.E. = 0.009, p= 2.34x 10
-04). It is 
noteworthy that this SNP is not identified as showing significant evidence of pleiotropy by 
the HEIDI-outlier test (its association with breast cancer is bbreast_cancer = -0.010, p = 0.44). 
The GWAS of CPD in UK Biobank identified five independent SNPs associated with 
heaviness of smoking. Two SNPs showed evidence of pleiotropy. Using the remaining three 
SNPs, the estimated causal effect of heaviness of smoking on schizophrenia was 0.22 (S.E. = 
0.07, p = 0.001). Adjusting for CPD reduced the number of genome-wide significant SNPs 
that could be used as instruments from 150 to 123. However, the estimated causal effect of 
schizophrenia on breast cancer after removing 8 SNPs with evidence of pleiotropy was 
larger and more significant after adjusting for heaviness of smoking (n instruments = 115; 
bxy = 0.051; S.E.  = 0.009; p = 6.8 x 10
-8). 
 
Adjusting for parity 
The estimated causal effect of reduced parity on breast cancer estimated from 10 SNPs with 
p < 10-07 was 0.149 (S.E. = 0.154, p = 0.330). Despite the causal estimate not being 
significant, we conducted the mtCOJO analysis to adjust the breast cancer summary 
statistics for the effect of reduced parity.  
A total of 137 genome-wide significant SNPs for schizophrenia which overlapped 
with the parity GWAS in UK Biobank were used as instruments to test for a causal effect on 
the adjusted breast cancer statistics. After removing 10 SNPs that failed the HEIDI test, the 
causal effect of schizophrenia on bc_adj_parity was larger and more significant than the 
estimate without adjustment (bxy = 0.043, S.E. = 0.009, p = 2.42 x 10
-06).  
 
Discussion:  
Our results provide strong evidence that the association of increased risk of breast cancer in 
schizophrenia patients reported from epidemiological studies is, at least partly, driven by 
shared genetic risk factors between the disorders. Epidemiological studies of first-degree 
relatives have shown inconsistent results with some studies showing that mothers with a 
child diagnosed with schizophrenia are at decreased risk of breast cancer (5, 24), while 
another study found no evidence of decreased risk (25). The latter study was the only study 
that compared rates in mothers of patients to those of other mothers, thus controlling for 
the effect of being a parent. The only study to investigate the rates in sisters of 
schizophrenia patients found no evidence of a significant difference in risk compared to the 
general population (24).  
 In conducting MR analyses, several SNPs were excluded by HEIDI-outlier, and these 
variants may have pleiotropic effects on both disorders. After excluding these outliers, using 
GSMR we find evidence that SNPs associated with schizophrenia are associated with breast 
cancer: under the assumption of causality, the predicted OR for breast cancer associated 
with a one standard deviation increase in schizophrenia is 1.09. This risk is modest but 
consistent with the small increased risk identified by large observational studies. 
Conversely, the GSMR estimate of the causal effect of breast cancer on schizophrenia was 
not significantly different from zero. If genetic risk factors were only pleiotropic between 
disorders, then there would be no expectation that the magnitude of SNP effect sizes of 
schizophrenia associated SNPs would be correlated with the magnitude of SNP effect sizes 
in breast cancer. This unidirectional relationship is more consistent with a model in which 
genetic factors for schizophrenia are on a causal pathway influencing breast cancer risk, 
rather than purely pleiotropic effects of shared genetic factors.  
 The MR framework is a powerful paradigm for inferring causality since the cases and 
controls included in the breast cancer GWAS are unlikely to be enriched for schizophrenia 
cases due to non-genetic confounding factors, and because genetic variants are assigned at 
birth, genetic data are free from a number of confounders and biases that are inherent in 
observational studies. Moreover, it is a cost-effective way to investigate direction of 
causality because the alternative observational study requires following large cohorts of 
breast cancer patients or schizophrenia patients over a long period of time.  
 There are some limitations in interpreting the results. We cannot get insight into the 
specific mechanism driving the directional relationship between schizophrenia risk and 
breast cancer risk. We performed two sensitivity analyses to investigate the possible effect 
of smoking, first removing a SNP known to be associated with both schizophrenia and 
smoking, and second adjusting the schizophrenia summary statistics for the potential causal 
effects of smoking heaviness. However, the GSMR estimate of causal effect of schizophrenia 
on breast cancer remained significant. Likewise, we conducted a conditional analysis to 
adjust breast cancer for the causal effect of parity, and found that the estimated causal 
effect of schizophrenia was not altered. These results suggest that the mechanism is not 
related to smoking or parity, but it is important to note that only a small number of 
instruments were available for smoking and parity meaning the causal effects of these traits 
are estimated with substantial error. Larger studies will allow for further dissection of the 
relationships between risk factors for breast cancer.  
Another possible mechanism underlying this causality is treatment with 
antipsychotics. Antipsychotics, especially risperidone, are known to increase the levels of 
prolactin (26), a neuroendocrine hormone that is elevated during pregnancy and lactation., 
There is some evidence that elevated prolactin levels are a risk factor for breast cancer 
{Gabrielson, 2018 #922}(Gabrielson et al; in press) and although no association has been 
found  between risperidone use and risk of breast cancer, the average follow up time for 
risperidone use was 1.29 years (SD = 1.35) and so longer-term use may still increase breast 
cancer risk (27). However, it is possible that the causal association is due to another 
unmeasured confounding variable that is highly genetically associated with both 
schizophrenia and breast cancer.  
 Another limitation is that this study has only evaluated breast cancer in women. It is 
possible that having schizophrenia also increases risk for breast cancer in men, but breast 
cancer is rare in men and the breast cancer GWAS included only women.  
 Our results suggest that investigations of the relationship between schizophrenia 
and breast cancer at the genetic level may prove fruitful for understanding the biology of 
breast cancer. Moreover, there needs to be increased awareness in the psychiatry 
community of the elevated risk of breast cancer in women with schizophrenia and 
encouragement of patients to seek screening for breast cancer.   
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Figure 1a GSMR plot for schizophrenia as exposure and breast cancer as outcome. Dotted 
line shows the GSMR estimate of causal effect.  
 
 
 
 
 
 
Figure 1b GSMR plot for breast cancer as exposure and schizophrenia as outcome 
 
